New World pulls back on Causeway Bay acquisition amid uneven recovery


Hong Kong’s New World Development (NWD) has shelved plans to acquire the remaining stakes in three commercial sites in Causeway Bay, signalling continued caution among developers despite signs of improving demand in the core office market.

The company, which has been selling assets to reduce debt, said it would “exercise prudence as appropriate, having regard to cost and efficiency, as well as overall market supply and demand, with a view to delivering reasonable returns”.

NWD, which reported total debt of HK$144.3 billion (US$18.4 billion) as of December, had applied in October for a compulsory sale to buy out minority owners of the sites at Percival Street, Russell Street and Lee Garden Road.
Such sales allow developers to force the sale of ageing buildings once ownership thresholds – typically between 65 and 90 per cent, depending on factors such as age and location – are met, facilitating redevelopment and, in some cases, boosting housing supply.

The move comes as analysts point to a two-speed recovery in Hong Kong’s commercial property market

Hong Kong’s New World Development has shelved plans to acquire the remaining stakes in three commercial sites in Causeway Bay. Photo: Jelly Tse
Hong Kong’s New World Development has shelved plans to acquire the remaining stakes in three commercial sites in Causeway Bay. Photo: Jelly Tse

“Currently, recovery is mainly in the core Central office leasing market; other office sectors and the broader retail market remain under pressure,” said Alkan Au, head of value and risk advisory for Hong Kong and Macau at JLL.

  • Related Posts

    India rations LPG supplies as Hormuz conflict disrupts West Asia imports – Firstpost

    India has rationed LPG supplies and barred piped natural gas users from buying cylinders as disruptions in the Strait of Hormuz hit fuel imports from West Asia, forcing refiners to…

    Continue reading
    Eli Lilly’s one-shot gene therapy shows promise in cutting ‘bad’ cholesterol – Firstpost

    Eli Lilly said its experimental gene-editing therapy cut LDL, or “bad,” cholesterol by up to 62% in an early-stage trial, raising hopes for a one-time treatment to help prevent heart…

    Continue reading

    Leave a Reply

    Your email address will not be published. Required fields are marked *